SBH
SUPN icon

Segall Bryant & Hamill’s Supernus Pharmaceuticals SUPN Stock Holding History

Segall Bryant & Hamill’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
25,931
+2,762
+12% +$133K 0.01% 527
2026
Q1 		$1.2M Sell
23,169
-64
-0.3% -$3.26K 0.02% 488
2025
Q4 		$1.15M Buy
23,233
+6,089
+36% +$296K 0.02% 495
2025
Q3 		$819K Sell
17,144
-6,506
-28% -$262K 0.01% 517
2025
Q2 		$745K Sell
23,650
-1,679
-7% -$53.8K 0.01% 519
2025
Q1 		$830K Hold
25,329
– – 0.01% 518
2024
Q4 		$916K Sell
25,329
-48
-0.2% -$1.69K 0.01% 520
2024
Q3 		$791K Buy
+25,377
New +$792K 0.01% 525

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Segall Bryant & Hamill's SUPN Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Supernus Pharmaceuticals (SUPN) stake by 12% in Q2 2026, buying an estimated $133K and bringing the position to 25,931 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #527.

Segall Bryant & Hamill first reported a position in SUPN in Q3 2024 and has held it in 8 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Segall Bryant & Hamill held 25,931 shares of Supernus Pharmaceuticals worth $1.21M as of Q2 2026.
  • Segall Bryant & Hamill bought 2,762 Supernus Pharmaceuticals shares in Q2 2026, an estimated $133K.
  • Supernus Pharmaceuticals made up 0.01% of Segall Bryant & Hamill's portfolio in Q2 2026, its #527 holding.
  • Segall Bryant & Hamill first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.